Blue Venture Fund and McKesson Ventures returned to reinvest in the cancer care analysis platform through a round that almost doubled its overall funding.
US-based cancer care technology provider Oncology Analytics has closed a $28m series C round featuring representatives of health insurance association Blue Cross Blue Shield and care product supplier McKesson.
Blue Venture Fund and McKesson Ventures joined venture capital and private equity firm Baird Capital, which led the round, and growth equity fund Oak HC/FT.
Founded in 2015, Oncology Analytics has built a data-powered software platform that helps oncology professionals accurately determine cancer treatments such as chemotherapy, radiotherapy and precision medication…
